Document is current
Any future updates will be listed below
-
Authors
Feng, Chu-Han https://orcid.org/0000-0003-3967-8831
Peltier, Linda https://orcid.org/0000-0002-6034-2956
Chouleur, Tiffanie
DiPonzio, Milea https://orcid.org/0009-0003-1753-1940
Aubry, Isabelle
Poirier, Alexandre J
Cordova, Zuzet M
Shen, Yunyun
Tabariès, Sébastien https://orcid.org/0000-0003-3513-6111
Cao, Xiaona
Chen, Guojun
Bikfalvi, Andreas https://orcid.org/0000-0003-4138-5229
Vidal, Silvia M
Siegel, Peter M https://orcid.org/0000-0002-5568-6586
Laneuville, Pierre
Tremblay, Michel L https://orcid.org/0000-0002-0281-541X
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (FDN-159923)
Genome Canada (PT 103179)
The Richard and Edith Strauss Foundation
FRQ | Santé
The Cedars Cancer Foundation
Genome Quebec
- License Information
-
More Information
Article History
Received: 7 August 2025
Revised: 14 February 2026
Accepted: 26 February 2026
First Online: 15 April 2026
Disclosure and competing interests statement
: Michel L. Tremblay is a founder of Kanyr Pharma Inc., a company developing small-molecule inhibitors of protein tyrosine phosphatases.
